Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. S. Karlsson, G. Anderson, M. Thompson, A. Hutchinson, L. Irving, B. Levy (Stockholm, Sweden; Melbourne, Australia; Boston, United States Of America). Anti-inflammatory lipoxin A4 is diminished in acute, severe exacerbations of COPD. Eur Respir J 2008; 32: Suppl. 52, 3110

Member's Comments

No comment yet.

Related content which might interest you: Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Chronic obstructive pulmonary disease is characterized with suppressed lipoxin A4 and increased lipoxin receptor expression in lungs Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 N-acetylcysteine for the treatment of acute exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002 Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Altered inflammasome activity in bacterial acute exacerbations of COPD (AECOPD) Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Markers of severity and inflammatory profile during exacerbations of severe asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Corticosteroid reversibility testing and exhaled leukotriene B4 in patients with stable, severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 252s Year: 2002 Neutrophil elastase in severe COPD and asthma exacerbation Source: Eur Respir J 2006; 28: Suppl. 50, 36s Year: 2006 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Antibiotics in acute exacerbation of asthma and COPD Source: Eur Respir Monogr 2017; 75: 150-158 Year: 2017 COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015